Can Semax and BPC-157 be combined?
There are no published studies directly analyzing Semax and BPC-157 combined together. Therefore, any answer must be built on an understanding of what each compound does on its own. This requires reasoning about whether their mechanisms are likely to be synergistic or conflicting. This is different from pointing to a study that actually tested this combination. It can be said that both compounds work through largely different biological systems. This at least reduces the likelihood of a direct pharmacological conflict. However, this does not prove that the combination is beneficial. Nor is it well enough researched to call it low risk with certainty.
BPC-157 is a synthetic peptide fragment derived from a protein found in gastric juice. It is primarily studied—aside from the collection of Semax research reviewed here—for its effects on tissue healing. This includes effects on tendons, muscles, intestinal lining, and blood vessel formation. Semax, on the other hand, focuses almost entirely on the central nervous system. Its most documented effects include increasing BDNF and NGF, neuroprotection after brain injury, and modulation of neurotransmitter systems like dopamine, serotonin, and GABA [1], [2]. These are really different areas of the body. One is largely peripheral tissue repair. The other is largely central nervous system function. Partly because of this, people interested in combining them usually frame that combination as addressing two distinct goals at once. They generally do not expect either compound to enhance the specific effects of the other.
What are the theoretical benefits of combining Semax and BPC-157?
Since no combination study exists, any discussion of benefit must clearly remain in the territory of theoretical reasoning. This reasoning is based on the individually documented properties of each compound. Consider someone dealing with a physical injury requiring tissue repair, alongside cognitive or brain-related goals. For example, someone recovering from a musculoskeletal injury while wanting cognitive support during a demanding period. The appeal of combining the two compounds is in addressing both needs simultaneously. Semax would focus on the brain-related goals. BPC-157 would focus on the physical side of tissue healing. This is a sensible practical rationale. It is important, however, to clearly state: this is not the same as proof that their combination elicits any effect beyond what each would do independently on its own.
One area of potential overlap is worth mentioning. Semax has documented effects on vascular gene expression and blood flow. This includes modulation of the VEGF family of genes involved in blood vessel formation and repair [3]. BPC-157 is also widely discussed for its angiogenic properties in its own separate research base. If both compounds do indeed affect blood vessel formation and repair processes—even through different specific mechanisms—then there is at least a plausible basis for thinking their effects on vascular repair could be complementary. This, however, remains entirely untested.
Are there risks to combining Semax and BPC-157?
Without any direct study of the combination, the responsible answer is: the risk profile of combining these two compounds is truly unknown. It is neither definitively low nor high. One can say that no individual studies of these compounds have identified obvious safety signals that would predict a dangerous interaction between them specifically. Semax's documented risks center around effects on blood clotting [4] and dopaminergic potentiation with stimulants [5]. Neither of these risks has an obvious direct overlap with what is typically discussed in the context of BPC-157's safety profile. This lack of an obvious warning sign is reassuring to a limited extent. However, it is not the same as having actual safety data for the combination. Any individual combining unstudied compounds should understand that they are acting without a direct evidence base in either direction.
What would the Semax and BPC-157 protocol look like?
Since no formal protocol has been established or validated by research, any specific dosing schedule discussed for this combination in online communities reflects user-generated practice. It is not a scientifically derived recommendation. The most commonly discussed approach separates these two compounds by purpose and sometimes by timing. Semax is administered intranasally for its central nervous system effects. BPC-157 is administered by its own typical route—often subcutaneously near an injury site or systemically—for tissue-specific purposes. This is distinct from combining them into a single mixed preparation. Treating them as two distinct interventions addressing two distinct goals is a more scientifically sound way to conceptualize this combination. This is preferable to treating them as one combined formulation with its own unique synergistic effect, given the current lack of research.
Can Semax be combined with Dihexa?
No published studies have analyzed Semax and Dihexa when administered together. However, there's an interesting mechanistic reason why this particular combination is frequently discussed. Dihexa is a compound explored outside of this research collection. It is known for its effects on hepatocyte growth factor (HGF) and its receptor c-Met. This is a signaling pathway involved in promoting synaptic connectivity and neuroplasticity. Semax's best-documented mechanism involves a different, yet related growth factor pathway: increasing BDNF and NGF [1], [6]. One review article specifically grouped Semax and Dihexa together as neuroactive peptides. It described them as compounds that enhance brain-derived neurotrophic factor and the HGF/c-Met pathways crucial for neuroplasticity [7]. This suggests that researchers reviewing the broader field of peptide therapeutics see these two compounds as operating in a similar conceptual space. They operate, however, through distinct molecular pathways—BDNF/TrkB for Semax, HGF/c-Met for Dihexa.
This type of pathway complementarity is the theoretical basis that people link these compounds to. Two different growth factor systems both converge on supporting neuroplasticity. The reasoning is that impacting neuroplasticity support from two distinct molecular angles can elicit a broader effect than relying on one pathway alone. This remains a reasonable hypothesis rather than a demonstrated finding. The actual combination has never been tested in any controlled study.
What are the benefits of Semax and Dihexa together?
Since this specific combination has not been studied, any discussion of benefits describes a theoretical rationale rather than a confirmed outcome. The rationale is based on one idea. BDNF/TrkB signaling—the main documented pathway for Semax—and HGF/c-Met signaling—the main studied pathway for Dihexa—are somewhat distinct roads. Both ultimately support synaptic plasticity and neuronal connectivity. This means that combining factors acting on each pathway separately could theoretically elicit more comprehensive neuroplastic support than either alone. Whether this theoretical additive benefit actually materializes in practice, and to what magnitude, simply has not been tested.
Can Semax be combined with NAD+?
No published studies have examined Semax in combination with NAD+ or NAD+ precursor compounds such as nicotinamide riboside or nicotinamide mononucleotide. These compounds operate through largely separate biological systems. NAD+ is central to cellular energy metabolism, mitochondrial function, and processes such as DNA repair via activation of sirtuin enzymes. The main documented mechanisms of Semax include neurotrophin signaling, neurotransmitter modulation, and changes in gene expression related to inflammation and neuroprotection [1], [8]. This relative separation between the main mechanisms of both compounds suggests a lower likelihood of direct pharmacological conflict. However, it also means there is a limited mechanistic basis for expecting a strong synergistic effect. Each compound would most likely simply do its own thing independently in parallel.
One area of potential overlap is worth mentioning. Semax has documented protective effects on mitochondrial function during periods of calcium stress and glutamate toxicity. It delays the collapse of mitochondrial membrane potential in neurons exposed to excitotoxic conditions [9]. NAD+ is fundamentally linked to mitochondrial energy production and health. Therefore, there exists at least a plausible rationale for considering that combining a compound that supports mitochondrial resilience under stress (Semax) with one that directly supports mitochondrial metabolic capacity (NAD+) could be mechanistically complementary. However, this remains speculative reasoning, not evidence.
What is the combination of Semax and Cerebrolysin?
This is one of the few combinations in this article where actual comparative studies exist. Even so, the two compounds were not tested together as a combined treatment. They were tested side-by-side in the same study for comparison. The researchers assessed both Cerebrolysin and Semax for their trophic effects on cultured rat pheochromocytoma (PC12) cells. They found a really significant difference between them. Cerebrolysin induced clear morphological signs of cell differentiation. It also improved cell survival under serum-free conditions, actively reducing the percentage of dying (apoptotic) cells. Semax did not induce a comparable trophic effect on these specific cells in this specific experimental context [10]. The researchers concluded that Cerebrolysin's neuroprotective effects are likely due to direct trophic action on cells. Semax's protective effects in other contexts appear to function through entirely different mechanisms, not the same type of direct cellular trophic support [10].
This is a truly useful finding for anyone considering this combination. It suggests that both compounds may act through significantly different, complementary mechanisms rather than redundant ones. Cerebrolysin offers more direct cellular trophic support properties. Semax offers gene expression, neurotransmitter, and inflammation-modulating effects. However, this study only compared both compounds side-by-side in an isolated cell model. It did not test them in combination in a live animal or human. Drawing conclusions about an actual combined protocol is still beyond what this study specifically supports.
Which compounds work best with Semax based on available research?
Looking at all available research, one compound stands out with the most direct comparative data and combination studies: Selank. This is due to the shared research history between these two peptides. It is also due to a direct comparative study of functional connectivity conducted in the same group of healthy human volunteers [11]. Beyond Selank, the combinations discussed above—BPC-157, Dihexa, NAD+, and Cerebrolysin—all represent theoretically plausible combinations based on complementary yet distinct mechanisms. However, none of them have actual studies of combined use behind them. The honest overall picture is this: what works best with Semax remains largely an open question. Current studies have not directly answered this for any combination beyond Semax and Selank.
What is the combination of Semax and fenbendazolu?
This is a combination that appears in some online discussion forums. However, it is important to state clearly and directly: there are no scientific studies linking Semax and fenbendazol in any way. These two compounds belong to completely unrelated pharmacological categories. There is no documented common mechanism, shared research history, or rational basis for combining them in any of the peer-reviewed literature reviewed here.
Fenbendazol is an antiparasitic drug. Specifically, it is a benzimidazole compound. It has been used in veterinary medicine to treat parasitic worm infections in animals. It works by disrupting microtubule formation in parasites. This is a completely different class of compound than Semax. Semax is a neuroactive peptide that acts through entirely distinct biological pathways. These include neurotrophin signaling, neurotransmitter modulation, and changes in gene expression in brain tissue [1], [2]. There is no overlapping mechanism between the antiparasitic benzimidazole compound and the neuroprotective peptide. There is no scientific justification whatsoever for combining them.
Why are people discussing this combination?
The interest in fenbendazol in combination with various other compounds, including Semax, appears to stem from unrelated online discussions about fenbendazolu. These discussions circulated separately from any research context specific to Semax. They are often linked to broader and largely unsubstantiated claims about fenbendazolu in areas far beyond its established veterinary antiparasitic use. When two unrelated compounds attract attention in online wellness or biohacking communities, people commonly begin to discuss them together. This usually happens simply because both are discussed within overlapping communities. It does not happen because there is any actual scientific or pharmacological basis linking them.
Is it safe to combine Semax and fenbendazol?
There are no studies that directly address this question. Semax’s research portfolio covers neuroscience, neuroprotection, and the physiology of stress. There is no significant overlap with veterinary antiparasitic pharmacology fenbendazolu. Therefore, there is no established scientific framework for assessing the specific risk of interactions between them. This does not mean that a dangerous interaction necessarily exists. It means that there is no research base from which to draw any conclusion, positive or negative, about their combination. This is a significantly different and more uncertain situation than even the other combinations discussed in this article. Those other combinations at least involve compounds with some conceptual or mechanistic link to the known effects of Semax. Fenbendazol simply lacks such a link.
What do the studies actually say about Semax and fenbendazolu?
Nothing. There are no published studies. There are no case reports. There are no animal studies. There is no clinical data of any kind analyzing Semax and fenbendazol together. Any claims about specific effects, benefits, or protocols for this combination circulating online are not supported by anything in the scientific literature. They should be viewed with significant skepticism. Given the complete lack of any scientific rationale linking these two very different types of compounds, combining them would constitute a completely unstudied and unsupported practice. This is true even by the more permissive standards applied to certain other unexplored combinations discussed elsewhere in this article.
Disclaimer
This content is intended solely for educational, informational, and scientific purposes. It should not be interpreted as medical advice, a diagnosis, or a treatment recommendation. Semax remains an investigational compound in most countries, including the United States and most European countries. It is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and used clinically in Russia and some Eastern European countries. None of the combinations discussed in this article—Semax with BPC-157, Dihexa, NAD+, Cerebrolysin, or fenbendazol — has been directly studied in humans or animals as combined protocols. The reasoning presented here is based on separate studies of each individual compound, not on tested data regarding the combinations.
References
[1] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[3] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborska, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2013). Effect of Semax and its C-terminal fragment Pro-Gly-Pro on the Expression of VEGF Family Genes and Their Receptors in Experimental Focal Ischemia of the Rat Brain. Journal of Molecular Neuroscience, 49(2), 328–333. https://doi.org/10.1007/s12031-012-9853-y
Grigorjeva, M. E., & Lyapina, L. A. (2010). Anticoagulation and antiplatelet effects of semax under conditions of acute and chronic immobilization stress. Bulletin of Experimental Biology and Medicine, 149(1), 44–46. https://doi.org/10.1007/s10517-010-0871-x
Eremin, K. O., Saransaari, P., Oja, S., & Raevskiĭ, K. S. (2004). Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice. Experimental and Clinical Pharmacology, 67(2), 8–11. PMID: 15188751
Shadrina, M. I., Dolotov, O. V., Grivennikov, I. A., Slominsky, P. A., Andreeva, L. A., Inozemtseva, L. S., Limborska, S. A., & Myasoedov, N. F. (2001). Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience Letters, 308(2), 115–118. https://doi.org/10.1016/s0304-3940(01)01994-2
[7] Rahman, O. F., Lee, S. J., & Seeds, W. A. (2026). Therapeutic peptides in orthopaedics: Applications, challenges, and future directions. Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews, 10(1), e25.00236. https://doi.org/10.5435/JAAOSGlobal-D-25-00236
[8] Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Sudarkina, O. Yu., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2020). Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischemia-reperfusion in rats. Genes, 11(6), 681. https://doi.org/10.3390/genes11060681
Storozhevykh, T. P., Tukhbatova, G. R., Senilova, Ya. E., Pinelis, V. G., Andreeva, L. A., & Myasoyedov, N. F. (2007). Effects of semax and its Pro-Gly-Pro fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity. Bulletin of Experimental Biology and Medicine, 143(5), 601–604. https://doi.org/10.1007/s10517-007-0192-x
Safarova, E. R., Shram, S. I., Grivennikov, I. A., & Myasoedov, N. F. (2002). Trophic effects of nootropic peptide preparations cerebrolysin and semax on cultured rat pheochromocytoma. Bulletin of Experimental Biology and Medicine, 133(4), 401–403. https://doi.org/10.1023/a:1016270626439
[11] Panikratova, Ya. R., Lebedeva, I. S., Sokolov, O. Yu., Rumshiskaya, A. D., Kupriyanov, D. A., Kost, N. V., & Myasoedov, N. F. (2020). Functional connectomic approach to studying Selank and Semax effects. Doklady Biological Sciences, 490(1), 9–11. https://doi.org/10.1134/S001249662001007X